ECSP077318A - Analogos de biaril piperazinil-piridina sustituidos - Google Patents
Analogos de biaril piperazinil-piridina sustituidosInfo
- Publication number
- ECSP077318A ECSP077318A EC2007007318A ECSP077318A ECSP077318A EC SP077318 A ECSP077318 A EC SP077318A EC 2007007318 A EC2007007318 A EC 2007007318A EC SP077318 A ECSP077318 A EC SP077318A EC SP077318 A ECSP077318 A EC SP077318A
- Authority
- EC
- Ecuador
- Prior art keywords
- analogs
- biaril
- piridina
- piperazinil
- replaced
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- -1 biaryl piperazinyl-pyridine analogs Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 244000144972 livestock Species 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen análogos de biaril piperazinil-piridina sustituídos de la Fórmula En donde las variables son como ya se ha descripto en la presente. Tales compuestos son ligantes que pueden utilizarse para modular la actividad de un receptor específico in vivo o in vitro, y que son particularmente útiles en el tratamiento de cuadros asociados con la activación patológica de los receptores en seres humanos, animales domésticos y ganado. También se proporcionan las composiciones farmacéuticas y los métodos para usar dichos compuestos en el tratamiento de esos desórdenes, así como métodos para usar dichos ligantes para estudios de localización de receptores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60172104P | 2004-08-13 | 2004-08-13 | |
| US64179605P | 2005-01-05 | 2005-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077318A true ECSP077318A (es) | 2007-04-26 |
Family
ID=36000525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007318A ECSP077318A (es) | 2004-08-13 | 2007-03-13 | Analogos de biaril piperazinil-piridina sustituidos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7662830B2 (es) |
| EP (1) | EP1786800B1 (es) |
| JP (1) | JP4955554B2 (es) |
| KR (1) | KR20070046924A (es) |
| CN (1) | CN101014587B (es) |
| AR (1) | AR050194A1 (es) |
| BR (1) | BRPI0514319A (es) |
| CA (1) | CA2577301C (es) |
| CR (1) | CR8992A (es) |
| EC (1) | ECSP077318A (es) |
| HN (1) | HN2007006799A (es) |
| IL (1) | IL181040A0 (es) |
| MA (1) | MA28857B1 (es) |
| MX (1) | MX2007001696A (es) |
| MY (1) | MY145822A (es) |
| NI (1) | NI200700040A (es) |
| NO (1) | NO20071243L (es) |
| NZ (1) | NZ553388A (es) |
| PE (1) | PE20060620A1 (es) |
| RU (1) | RU2413726C2 (es) |
| SG (1) | SG157399A1 (es) |
| TW (1) | TW200605889A (es) |
| WO (1) | WO2006026135A2 (es) |
| ZA (1) | ZA200701530B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2264014A1 (en) | 2001-08-31 | 2010-12-22 | Université Louis Pasteur | Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors |
| AU2004257289A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| EP1812007B1 (en) | 2004-11-02 | 2011-09-07 | Northwestern University | Pyridazine compounds and methods |
| WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
| CA2590299A1 (en) * | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| EP1838703A2 (en) * | 2005-01-19 | 2007-10-03 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| WO2007127474A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| US20090325973A1 (en) * | 2006-04-28 | 2009-12-31 | Watterson D Martin | Formulations containing pyridazine compounds |
| WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
| DK2142529T3 (da) * | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| EP2683243A4 (en) * | 2011-03-09 | 2014-12-03 | Celgene Avilomics Res Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| ES2390326B1 (es) * | 2011-04-05 | 2013-08-14 | Universidad Miguel Hernández De Elche | Antagonistas de trpv1 y sus usos. |
| EP2771337B1 (en) | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
| EP2785690B1 (en) * | 2011-12-02 | 2016-07-13 | Boehringer Ingelheim International GmbH | Piperidine derivatives, pharmaceutical compositions and uses thereof |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2015014836A1 (en) | 2013-07-30 | 2015-02-05 | Janssen R&D Ireland | Substituted pyridine-piperazinyl analogues as rsv antiviral compounds |
| CN115060832B (zh) * | 2022-08-18 | 2022-11-29 | 上海奥科达生物医药科技有限公司 | 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4921148B1 (es) | 1970-12-28 | 1974-05-30 | ||
| US3775326A (en) | 1972-04-17 | 1973-11-27 | Addressograph Multigraph | Pressure fixable electroscopic printing powder |
| FR2262512A1 (en) | 1974-03-01 | 1975-09-26 | Synthelabo | 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity |
| DE2643753A1 (de) * | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
| FI70411C (fi) | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
| DE3609596A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| WO1992004333A1 (fr) * | 1990-08-31 | 1992-03-19 | Nippon Shinyaku Co., Ltd. | Derive de pyrimidine et medicament |
| CA2197091A1 (en) | 1994-08-08 | 1996-02-22 | Fusao Ueda | Triazine derivative and medicine |
| US5962453A (en) * | 1995-08-08 | 1999-10-05 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
| TW520362B (en) | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| CN1312807A (zh) * | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| KR20020005653A (ko) * | 1999-04-01 | 2002-01-17 | 실버스타인 아써 에이. | 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘 |
| WO2001070728A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
| EP1136483A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
| AU2001268718B2 (en) * | 2000-06-29 | 2006-01-05 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| AU8066701A (en) * | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| DK1397351T3 (da) * | 2001-06-01 | 2010-01-18 | Hoffmann La Roche | Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer |
| WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| ES2412273T3 (es) * | 2002-11-21 | 2013-07-10 | Novartis Ag | Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer. |
| WO2005007646A1 (en) * | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| AU2004257289A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| WO2005009980A1 (en) * | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| CA2590299A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| EP1838703A2 (en) | 2005-01-19 | 2007-10-03 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| US8258143B2 (en) * | 2006-06-28 | 2012-09-04 | Duquesne University Of The Holy Ghost | Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer |
-
2005
- 2005-06-22 MY MYPI20052848A patent/MY145822A/en unknown
- 2005-07-01 TW TW094122269A patent/TW200605889A/zh unknown
- 2005-08-02 AR ARP050103213A patent/AR050194A1/es unknown
- 2005-08-11 PE PE2005000929A patent/PE20060620A1/es not_active Application Discontinuation
- 2005-08-13 BR BRPI0514319-5A patent/BRPI0514319A/pt not_active IP Right Cessation
- 2005-08-13 CN CN2005800275501A patent/CN101014587B/zh not_active Expired - Fee Related
- 2005-08-13 JP JP2007525874A patent/JP4955554B2/ja not_active Expired - Fee Related
- 2005-08-13 CA CA2577301A patent/CA2577301C/en not_active Expired - Fee Related
- 2005-08-13 ZA ZA200701530A patent/ZA200701530B/xx unknown
- 2005-08-13 WO PCT/US2005/028969 patent/WO2006026135A2/en not_active Ceased
- 2005-08-13 NZ NZ553388A patent/NZ553388A/en unknown
- 2005-08-13 MX MX2007001696A patent/MX2007001696A/es not_active Application Discontinuation
- 2005-08-13 US US11/204,202 patent/US7662830B2/en active Active
- 2005-08-13 KR KR1020077005831A patent/KR20070046924A/ko not_active Ceased
- 2005-08-13 RU RU2007106042/04A patent/RU2413726C2/ru not_active IP Right Cessation
- 2005-08-13 SG SG200907610-0A patent/SG157399A1/en unknown
- 2005-08-13 EP EP05810146.0A patent/EP1786800B1/en not_active Expired - Lifetime
-
2007
- 2007-01-29 IL IL181040A patent/IL181040A0/en unknown
- 2007-02-09 NI NI200700040A patent/NI200700040A/es unknown
- 2007-02-23 HN HN2007006799A patent/HN2007006799A/es unknown
- 2007-03-07 NO NO20071243A patent/NO20071243L/no not_active Application Discontinuation
- 2007-03-13 CR CR8992A patent/CR8992A/es not_active Application Discontinuation
- 2007-03-13 EC EC2007007318A patent/ECSP077318A/es unknown
- 2007-03-13 MA MA29749A patent/MA28857B1/fr unknown
-
2010
- 2010-02-15 US US12/705,964 patent/US8334382B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077318A (es) | Analogos de biaril piperazinil-piridina sustituidos | |
| NI200900023A (es) | Análogos de 2-fenoxi pirimidinona | |
| CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
| MX336549B (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| EA200971084A1 (ru) | 5-членные гетероциклические амиды и родственные соединения | |
| MY148461A (en) | Heteroaryl amide analogues as p2x7 antagonists | |
| CO6270312A2 (es) | Moduladores de gpr40 bifenilo-sustituidos | |
| SV2004001548A (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| UY30640A1 (es) | Compuestos | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| BRPI0512274A (pt) | derivados de piperazina aril-substituìdos | |
| NI201100184A (es) | Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida | |
| NI201100183A (es) | Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida | |
| TW200621251A (en) | Substituted biaryl quinolin-4-ylamine analogues | |
| NI201100185A (es) | Antagonistas de ccr3 de arilsulfonamida | |
| UY29478A1 (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos | |
| HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
| CO6280529A2 (es) | DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA | |
| CO6280527A2 (es) | Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa | |
| DOP2005000164A (es) | Analogos de biaril piperazinil-piridina sustituidos | |
| CR8825A (es) | Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6 | |
| CO6270315A2 (es) | Metodo para obtener derivados aromaticos de acido pentanoico con actividad de modulacion de la gamma secretasa | |
| TW200510383A (en) | Biaryl piperazinyl-pyridine analogues | |
| DE602004007141D1 (de) | Aryl-substituierte benzoädüisothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren |